

**Practitioner's Docket No. MPI99-037P1RCP1M****REMARKS**

In response to the Restriction Requirement dated September 30, 2002 (paper No. 10), Applicants hereby elect Group I-IV, drawn to a nucleic acid encoding a polypeptide having SEQ ID NO:2 (claims 1-7 and 12), with traverse. While clarification is requested, initial election is made selecting nucleic acid encoding a polypeptide of SEQ ID NO:11, presumably designated Group IV in the Office Letter.

Applicant wishes to traverse the Requirement and hereby requests rejoinder of Groups II-IV, which include nucleic acids encoding polypeptide of SEQ ID NO:5, 8, and 11. Applicant submits each of the sequences encode partial or full length human LGR6, and as such, a search of one Group would include a search of other Groups. Thus, joinder of these Groups II-IV would place no additional burden on the Examiner. In fact, lack of joinder of the Groups would place additional burden on Applicant and the Office in filing and search and exam of additional applications containing overlapping subject matter.

Applicant's election is made without prejudice to Applicant's right to pursue the additional subject matter in other applications. Applicant hereby reserves the right to traverse the above restriction with respect to non-elected Groups I, V-XXIV in this or subsequent applications.

Claims 1-22 have been cancelled and new claims 23-32 have been added. New Claims 23-32 are directed to the subject matter elected, that of original claims 1-7 and 12 (Groups II-IV). Support for the new claims lies in elected claims 1-7 and 12 and throughout the specification as filed. No new matter is added by virtue of the amendments made herein.

This paper is being filed timely and it is believed no additional fees or extensions of time are required. In the event any additional fees are necessary, the undersigned hereby authorizes the requisite fees to be charged to Deposit Account No. 501668.

Entry of the remarks made herein is respectfully requested.

Respectfully submitted,

MILLENNIUM PHARMACEUTICALS, INC.

By Kerri Pollard Schray  
Kerri Pollard Schray  
Registration No. 47,066  
75 Sidney Street  
Cambridge, MA 02139  
Telephone - 617-551-3676  
Facsimile - 617-551-8820

(Page 3 of 3)

Practitioner's Docket No. MPI99-037P1RCP1M**PATENT****IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of: Gu, Wei  
 Application No.: 09/891,595 Group No.: 1646  
 Filed: May 8, 2001 Examiner: P.M. Mertz  
 For: NOVEL G-PROTEIN COUPLED RECEPTORS AND USES THEREFOR

**Commissioner for Patents**  
**Washington, D.C. 20231**

**CHANGE OF ATTORNEY DOCKET NUMBER**

Dear Sir:

Please note that the Attorney Docket Number has been changed from MNI-080CP to MPI99-037P1RCP1M. Please reference MPI99-037P1RCP1M on all future correspondence.

Respectfully submitted,

11 October 2002

**MILLENNIUM PHARMACEUTICALS, INC.**

By Kerri Pollard Schray  
 Kerri Pollard Schray  
 Registration No. 47,066  
 75 Sidney Street  
 Cambridge, MA 02139  
 Telephone - 617-551-3676  
 Facsimile - 617-551-8820  
 Facsimile - 617-551-8820

**CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10\***

I hereby certify that, on the date shown below, this correspondence is being:

**MAILING**

deposited with the United States Postal Service in an envelope addressed to the Commissioner for Patents, Washington, D.C. 20231.  
**37 C.F.R. SECTION 1.8(a)**

**37 C.F.R. SECTION 1.10\***

with sufficient postage as first class mail.  as "Express Mail Post Office to Address"  
 Mailing Label No.

**TRANSMISSION**

transmitted by facsimile to the Patent and Trademark Office.

Signature

Kerri Pollard Schray  
 (type or print name of person certifying)

**\*WARNING:** *Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. Section 1.10(b). Since the filing of correspondence under [Section] 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.*